Search

Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.

… Wednesday, July 4, 2018 Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal

Researchers at MSK published updated data today in the New England Journal of Medicine from the ongoing, single-arm Phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations.

… Friday, May 29, 2020 Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data today in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with

Longtime donors Fiona and Stanley Druckenmiller have contributed a transformative gift of $100 million to MSK through their foundation. The gift will be used to launch the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

… Tuesday, January 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of the Fiona and Stanley Druckenmiller Presidential Innovation Fund. The new initiative, made possible by a transformative $100 million gift from the Fiona and Stanley Druckenmiller Foundation, is expected

Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.

… Sunday, June 4, 2023 New data led by researchers at Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Brigham Cancer Center featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in  The New England Journal of Medicine (NEJM

… Thursday, April 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia Paraskevi Tsamouri Awarded the 2025 Kravis WiSE Fellowships Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia

What inspires the outstanding young scientists who come from around the world to train at MSK?

… Thursday, September 11, 2025 Their stories are all different — the daughter of farmers in rural China, the first scientist in a family of English professors, the child from a small town in Italy who never stopped asking “Why?” But one thing unites them: They left behind family and friends, their familiar

… Wednesday, September 28, 2022 Alexis Lopez is a self-described “MSK baby,” due to the 23-year career he’s built at Memorial Sloan Kettering Cancer Center (MSK), as well as the three decades his mother, Amarilis, served as a patient financial representative at MSK before retiring in 2014. “MSK has always

Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer.

… Tuesday, October 15, 2013 Summary Memorial Sloan Kettering researchers say a drug that acts on noncancerous, tumor-infiltrating cells might provide a new treatment option for the most common and aggressive type of brain cancer. White blood cells called macrophages patrol almost every tissue of the body

Learn how MSK researchers are trying to understand how the immune system senses cancer in order to make better immunotherapies.

… Friday, March 14, 2025 One way our immune system protects us is by ridding our bodies of altered cells that could lead to cancer. But exactly how and when does our immune system sense cancer? How do tumors evolve to avoid being detected? And how can a better understanding of this process help develop

Read about some of the most important clinical advances made at MSK in 2020.

… Monday, December 21, 2020 In 2020, Memorial Sloan Kettering clinical researchers continued to make major discoveries that will improve the treatment of cancer and guide the development of new therapies. Many of these studies were made possible by philanthropic donations, which allow researchers to pursue